Dave Fornell, DAIC Editor

Dave Fornell, editor of DAIC Magazine

Blog | Dave Fornell, DAIC Editor | Structural Heart| November 04, 2019

Women Breaking the Glass Ceiling in Structural Heart

The first all-women panel discussion on structrual heart cases was held at TCT 2019. Rebecca Hahn, M.D., foreground, was the co-organizer of the Women in Structural Heart (WISH) evening session.

The first all-women panel discussion on structrual heart cases was held at TCT 2019. Rebecca Hahn, M.D., foreground, was the co-organizer of the Women in Structural Heart (WISH) evening session.

My observation over the 13 years covering cardiology is that it is a heavily male-dominated field. This is more pronounced in interventional cardiology conferences I attend, where less than 5 percent of operators are women. The divide is less at imaging conferences, particularly in cardiac ultrasound. So it should not be surprising that women appear to have found the most momentum over the past decade in imaging, and have made a rapid entrance into the intervention world. 

This was highlighted at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting in the first Women in Structural Heart (WISH) event. It was a packed, standing-room-only evening session made up of nearly all women speakers, structural heart patient case presenters and panelists. The only exception was Martin Leon, M.D., director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian/ Columbia University Medical Center, who has helped raise the bar for women in structural heart.

Unlike interventional cardiology, where the operator can largely work independently with their live fluoro in the cath lab, the advent of transcatheter structural heart interventions over the past decade requires a heart team approach where cardiac imaging plays a central role. This fact was driven home a few years ago at the Transcatheter Valve Therapeutics (TVT) meeting where Leon opened the meeting by stressing the need for a team, with one of the most valuable players being the interventional imager. He showed images of Rebecca Hahn, M.D., director of interventional echocardiography, NewYork-Presbyterian/Columbia University Medical Center and a professor of medicine at Columbia. Leon said without her, there is no way he could perform transcatheter structural heart procedures. 

Over the past decade, Hahn rapidly rose to become a sort of interventional imaging superstar with her work at Columbia. She is a top speaker at TCT, the American Society of Echocardiography (ASE) and several other conferences. Hahn has been author or co-author of more than 170 peer-reviewed articles in the last 10 years, and is the national principal investigator for the SCOUT clinical trial, an early feasibility study examining a percutaneous tricuspid valve annuloplasty system.

Working with the Cardiovascular Research Foundation (CRF), the sponsor of TCT, she co-organized the WISH session to showcase the accomplishments of women in structural heart. She worked with Vivian Ng, M.D., assistant professor of medicine and an interventional cardiologist at the NewYork-Presbyterian/Columbia University Medical Center Structural Heart and Valve Center, to bring together a who's who of women in structural heart for the event. 

"Women really are in the forefront of structural heart, and we are sometimes lost amongst the crowd," Ng explained. "Because this is such a multi-disciplinary field, there are women involved in imaging, interventional cardiology, surgery, nurse coordinators, heart failure specialists, and we really haven't had a way to come together as a community. WISH was created to be able to bring this community together and to show the contributions of women in the field to the community act large. We wanted to say 'here we are,' and that we are at the forefront and we have made large contributions to this field."

Ng said she has received positive feedback from female trainees at TCT, who said they never expected to see a large session and panels filled with thought-leading women. "I think it is great that we are able to highlight these role models and show the generation in training that we are here to help them," Ng said. 

Ng shares more about WISH in the VIDEO: Highlighting Women Involved With Structural Heart Interventions.

To help promote women in interventional cardiology, the Society for Cardiovascular Angiography and Interventions (SCAI) has created the Women in Innovations (WIN) program to foster professional development and collaboration among women. 

DAIC Editor Dave Fornell with some of the faculty of the Women in Structural Heart (WISH) - Breaking the Glass Ceiling session TCT 2019. Left to right are doctors Linda Gillam, Morristown Medical Center; Rebecca Hahn, Columbia University; Vivian Ng, New York Presbyterian; and Dee Dee Wang, Henry Ford Hospital.

DAIC Editor Dave Fornell with some of the faculty of the Women in Structural Heart (WISH) - Breaking the Glass Ceiling session TCT 2019. Left to right are doctors Linda Gillam, Morristown Medical Center; Rebecca Hahn, Columbia University; Vivian Ng, New York Presbyterian; and Dee Dee Wang, Henry Ford Hospital.

 

Related Content With WISH Presenters:

Women: Cardiology Needs You! — Blog by Linda Gillam, M.D.

VIDEO: What is Required for Interventional Echo — Interview with Rebecca Hahn, M.D.

VIDEO: The Importance of the Neo-LVOT in Transcatheter Mitral Valve Replacement — Interview with Dee Dee Wang, M.D.

VIDEO: The Value of the Cardiovascular Service Line — Interview with Linda Gillam, M.D.,

VIDEO: Can We Live in 3-D Echo? — Interview with Lissa Sugeng, M.D.

VIDEO: Tricuspid Valve Imaging and Interventions Developing Hand-in-hand — Interview with Rebecca Hahn, M.D.

VIDEO: Strategies to Avoid Acute Kidney Injury Caused by Cath Lab Contrast — Interview with Roxana Mehran, M.D.

VIDEO: Applications in Cardiology for 3-D Printing and Computer Aided Design — Interview with Dee Dee Wang, M.D.

VIDEO: TWILIGHT Trial Shows Benefit to Ticagrelor Monotherapy After Stent Implantation — Interview with Roxana Mehran, M.D.
 

 

Related Content

The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.

The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.

Feature | Heart Valve Technology | July 08, 2021
July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valv
The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1 to Gyrus Capital and Corcym..

The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1.

News | Heart Valve Technology | June 02, 2021
June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its...
If MitraClip Fails 95 Percent of Patients Will Need Full Surgical Valve Replacement according to a late-breaking study at the AATS 2021 meeting. #AATS2021

If MitraClip fails and a surgical repair is required, a late-breaking study presented at the 2021 AATS meeting showed 95 percent of patients will require a full surgical valve replacement.

News | Heart Valve Technology | May 04, 2021
May 4, 2021 – A new study, presented at the 2021 American Association f...
University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. This can be implanted in pediatric patients with congenital heart diseas. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

News | Heart Valve Technology | March 18, 2021
March 18, 2020 — A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the Coll
Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session.
News | Heart Valve Technology | February 04, 2021
February 4, 2021 — Transcatheter aortic valve replacement (TAVR) has historically only been used with caution in the
Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) so the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.
News | Heart Valve Technology | December 14, 2020
December 14, 2020 - Foldax Inc. today announced that the U.S.

The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. 

Feature | Heart Valve Technology | November 17, 2020
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, mor
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
November 17, 2020 — Boston Scientific Corp.